Information sheet on the clinical study - COMPASS

Main indication
Colon cancer
Study name (study type)
COMPASS: deCOMPressing stomA and two-stage elective resection vs. emergency resection in patients with left-sided colon cancer and obstructive ileus
Study sponsor
Dresden University of Technology
Registration number
Investigator Site File DRKS00031827
FOR SKIM READERS:
This study investigates whether, in patients with left-sided colon cancer and obstructive ileus, primary
creation of a decompressive stoma is superior to primary tumor resection in terms of mortality and
stoma-free survival.
DETAILED INFORMATION
The aim is to investigate whether a decompressive stoma, used as a temporary measure until elective surgery, reduces 120-day mortality compared to emergency resection in patients with obstructive left-sided colorectal cancer.
Study Title
COMPASS: deCOMPressing stomA and two-stage elective resection vs. emergency resection in
patients with left-sided colon cancer and obstructive ileus
Which conditions are being treated in the study?
Colon cancer
Are specific subgroups of patients with one of the mentioned conditions being treated?
Patients with left-sided colon cancer and obstructive ileus
Study Protocol.
The COMPASS study includes eight (control arm) or 12 (intervention arm) predefined study visits. Visits 10–12 occur every 12 months for up to 36 months after surgery.
Inclusion criteria
- Patients with acute, tumor-related left-sided colonic obstruction (from the splenic flexure to the rectum)
- Need for urgent surgical intervention (associated with clinical symptoms of ileus, e.g.,
abdominal distension, nausea, and/or vomiting) - Evidence of a dilated colon with or without small bowel dilation on CT or
X-ray imaging - Age ≥ 18 years and the presence of informed consent
Exclusion criteria
- Patients with rectal cancer (< 16.0 cm from the anal margin on rigid rectoscopy)
- Right-sided colon cancer
- Life expectancy < 90 days due to advanced cancer
- Signs of bowel perforation on CT or X-ray (evidence of free air)
- Locally advanced tumor disease with local infiltration of other structures, precluding
R0 resection without neoadjuvant chemotherapy - Patients who are not candidates for surgery (ASAScore ≥ IV)
- Patients with severe psychiatric or neurological disorders as well as
substance abuse
Your contacts: Investigators at the center and contact information
Mr. Nguyen, Trong Anh
Email: Tronganh.Nguyen@~@gp-ruesselsheim.de
Phone: 06142 88-1827
Staff members responsible at the study clinic
Heike Borchert (Study Coordinator)
Email: borchert@~@gp-ruesselsheim.de
Phone: 06142 88-1032